Genetic engineering is the direct manipulation of an organism's DNA using biotechnology tools and techniques. It involves the addition, deletion, or modification of genetic material to introduce new traits, correct defects, or study gene function. Unlike traditional selective breeding, which relies on natural recombination over many generations, genetic engineering allows scientists to make precise, targeted changes to an organism's genome in a single generation. The foundational techniques include recombinant DNA technology, molecular cloning, and more recently, programmable nuclease systems such as CRISPR-Cas9.
The field traces its origins to the early 1970s when Stanley Cohen and Herbert Boyer first demonstrated that DNA fragments from different organisms could be combined and propagated in bacteria. This breakthrough led to the production of recombinant human insulin in 1982, the first genetically engineered pharmaceutical approved for human use. Since then, the scope of genetic engineering has expanded dramatically to encompass genetically modified organisms (GMOs) in agriculture, gene therapy for hereditary diseases, industrial biotechnology for enzyme and biofuel production, and synthetic biology approaches that design entirely novel biological systems.
Today, CRISPR-Cas9 and related genome-editing technologies have transformed the field by making DNA modification faster, cheaper, and more accessible than ever before. Applications range from engineering disease-resistant crops and developing CAR-T cell therapies for cancer, to the controversial possibility of heritable human germline editing. These advances raise profound ethical, ecological, and regulatory questions about biosafety, equitable access, intellectual property, and the moral boundaries of altering living organisms. Understanding genetic engineering requires knowledge of molecular biology, ethics, and the regulatory frameworks that govern its use worldwide.